7097-09-8

Basic information

• Product Name: Leonurine
• Synonyms: Leonurine Benzoic acid
• CAS NO: 7097-09-8
• Molecular Formula: C14H21N3O5
• Molecular Weight: 0
• Mol File: 7097-09-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Leonurine(CAS DataBase Reference)
• NIST Chemistry Reference: Leonurine(7097-09-8)
• EPA Substance Registry System: Leonurine(7097-09-8)

Safety Data

• Hazardous Substances Data: 7097-09-8(Hazardous Substances Data)

Usage

General Description

Leonurine is a naturally occurring alkaloid found in the herb Leonurus cardiaca, also known as motherwort. It has been studied for its potential medicinal properties, including its ability to relax smooth muscles and improve cardiovascular health. Leonurine has been shown to have vasodilatory effects, potentially offering benefits for conditions such as hypertension and angina. It also exhibits antioxidant and anti-inflammatory properties, which may contribute to its cardiovascular protective effects. Additionally, leonurine has been investigated for its potential anti-cancer properties, showing promise in inhibiting the growth of cancer cells. Overall, leonurine has demonstrated a range of potential health benefits, though further research is needed to fully understand its mechanisms of action and potential therapeutic uses.

Upstream product

• 18780-68-2 4-ethoxycarbonyloxy-3,5-dimethoxy-benzoyl chloride 
• 147895-43-0 S-methylisothiourea hemisulphate 
• 18780-70-6 Leonuramin 
• 18780-67-1 4-[(ethoxycarbonyl)oxy]-3,5-dimethoxybenzoic acid 
• 2986-19-8 carbamimidothioic acid methyl ester 
• 6318-20-3 O-acetylsyringic acid 
• 867-44-7 S-Methylisothiourea sulfate 
• 530-57-4 3,5-dimethoxy-4-hydroxybenzoic acid 
• 322474-21-5 N,N'-bis-Boc-S-methyl-isothiourea 

Downstream Products

• 1470302-79-4 leonurine-O-glucuronide 

Relevant articles and documents

Design and synthesis of novel SCM-198 analogs as cardioprotective agents: Structure-activity relationship studies and biological evaluations

SCM-198 (Leonurine) has attracted great attention due to its cardioprotective effects in myocardial infarction (MI). However, no systematic modifications and structure-activity relationship (SAR) studies could be traced so far. In this study, 35 analogs of SCM-198 were designed, synthesized and their cardioprotective effects were evaluated. The cell viability assay on cardiomyocyte cell line H9c2 challenged with H2O2 showed that several analogs exhibited more potent cytoprotective effects than SCM-198 at 1 μM and 10 μM concentrations. LDH release level in cells treated with 1 μM 14o was comparable with cells treated with 10 μM SCM-198. Results of Bcl-2 expression and caspase-3 activation accordingly indicated higher protective activity of 14o than SCM-198. Moreover, in a mouse model of MI, the mice pretreated with 14o had much lower infarct size compared with that of SCM-198. The mechanism study suggested that 14o improved cardiac morphology and reduced apoptosis of cardiomyocytes in the border zone of infarction, as proved by H&E and TUNEL staining.

Six-step synthesis of Leonurine and toxicity study on zebrafish

Leonurine (1), an important ingredient in leonurus sibiricus L., can be used for some gynecological disease. We have developed a concise and efficient synthetic route of Leonurine, which can be optimized for mass production. Commercially available compound 6 and 2,3-dihydrofuran (7) were used as starting materials. And the toxicity study on zebrafish shows that Leonurine would promote the hatching of zebrafish embryos at low concentration and result in acute death or chronic lethal toxicity at high concentration.

Leonurine-cysteine analog conjugates as a new class of multifunctional anti-myocardial ischemia agent

The design, synthesis and biological evaluation of novel Leonurine-cysteine analog conjugates 3,5-dimethoxy-4-(2-amino-3-prop-2-ynylsulfanyl-propionyl)- benzoic acid 4-guanidino-butyl ester (1a), 3,5-dimethoxy-4-(2-animo-3- allysulfanyl-propionyl)-benzoic acid 4-guanidino-butyl ester (1b) and 3,5-dimethoxy-4-(3-(2-chlorocarbonyl-ethyldisulfanyl)-propionyl)-benzoic acid 4-guanidino-butyl ester (2) were reported in this paper. We tested their effects on hypoxia-induced neonatal rat ventricular myocytes. Our data showed that all of them had cardioprotective effects. Both of 1a and 1b were able to modulate hydrogen sulfide production, and 1a possessed higher biological activity than 1b and 2, which indicated that there was positive correlation between conjugates and their precursors. Furthermore we illuminated that the cardioprotective mechanism of 1a were related to increase SOD and CAT activity, decrease MDA and ROS level, protect some cell organs and regulate apoptosis-associated genes and proteins expression (bcl-2 and bax) via the caspase-3 pathway in molecular level. These results indicated that 1a had the potential to be a new class of multifunctional anti-myocardial ischemia agent. Most importantly, these results provided us important clues for the further design and modification of this type of Leonurine-cysteine analog conjugates in future.